LORETA drug
Evidence from:
primary |
all sources
Related entities (8)
| Subject | Relation | Object | p-value | Evidence |
|---|---|---|---|---|
| eLORETA | associated_with | LORETA | — | 1 |
| LORETA | associated_with | ERP | — | 1 |
| LORETA | associated_with | fMRI | — | 1 |
| LORETA | associated_with | gray matter | — | 1 |
| LORETA | associated_with | ORN component | — | 1 |
| LORETA | associated_with | ORP component | — | 1 |
| LORETA | associated_with | PET | — | 1 |
| LORETA | associated_with | structural MRI | — | 1 |
Mentioned in (3)
Papers in which this entity is mentioned.
- Resting-state network disruption and APOE genotype in Alzheimer's disease: a lagged functional connectivity study. (2012)
- Generator localization by current source density (CSD): implications of volume conduction and field closure at intracranial and scalp resolutions. (2012)
- Brain signatures of monetary loss and gain: outcome-related potentials in a single outcome gambling task. (2009)
Merged raw entities (2)
All extracted name/type variants the normalize job merged into this entity. Use this to spot wrong merges, or aliases that should be split off.
| Raw name | Type | Papers | Mentions |
|---|---|---|---|
| loreta | drug | 3 | 4 |
| low resolution brain electromagnetic tomography | drug | — | — |